Roberto Bellini, Bellus Health CEO
Bellus says its Merck cough rival passed a PhIIb test after earlier flop, but investors can't make up their minds
A little over a year after flopping out of the chronic cough game and leaving Merck as the sole player, Bellus Health is saying it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
